RxDoctor Payments Data

Alfredo Sanchez Cruz, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1619133857

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 50.3% of the total. Reporting peaked in 2019 at $8,883 and has fallen 90.3% since, to $861 in 2025.

$13,491in general payments, 2019–2025

Across 164 payments — averaging $82.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$7K
  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • Medtronic$712
  • Boehringer Ingelheim$615
  • Novo Nordisk$615
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$1,87014%
  • Speaking & faculty fees$6,23046%
  • Travel & lodging$6155%
  • Food & beverage$4,76035%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,491 in reported general payments places this provider in the 80th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,479
Medicare patients
17
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide456$456,972
OzempicSemaglutide257$410,088
JardianceEmpagliflozin502$344,002
MounjaroTirzepatide205$227,013
FarxigaDapagliflozin Propanediol292$203,925
Synjardy XrEmpagliflozin/Metformin Hcl124$89,322
JanuviaSitagliptin Phosphate115$83,743
SynthroidLevothyroxine Sodium1,373$82,668
Trijardy XrEmpaglifloz/Linaglip/Metformin108$78,206
GlyxambiEmpagliflozin/Linagliptin100$71,751
Janumet XrSitagliptin Phos/Metformin Hcl102$63,038
JanumetSitagliptin Phos/Metformin Hcl109$61,558
Xigduo XrDapaglifloz Propaned/Metformin97$60,169
LantusInsulin Glargine,hum.Rec.Anlog235$40,645
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$31,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$119$695,237740 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi, Tradjenta$615$632,184911 claims
Novo NordiskOzempic, Rybelsus$615$424,664270 claims
MerckJanuvia, Janumet Xr, Janumet$280$208,340326 claims
AstraZenecaFarxiga$1,340$203,925292 claims
AbbVieSynthroid$18$82,6681,373 claims
Sanofi-aventis U.S. LLCLantus, Soliqua 100-33$6,783$52,056246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →